 NEW YORK, Aug. 17, 2021 PRNewswire -- Petros Pharmaceuticals, Inc. Petros or the Company Nasdaq: PTPI, a leading provider of therapeutics for mens health, today announced financial results for the second quarter ended June 30, 2021. Second Quarter Highlights: Completed pilot label comprehension study to initiate process for STENDRA prescription erectile dysfunction medication to support the process for designation as over -the-counter treatment Initiated communications with the U.S. Food and Drug Administration regarding expansions to STENDRAs package insert label STENDRA net sales increased 123 during the second quarter of 2021 vs. 